- Company
- Lotte Biologics’ CMO business makes smooth progress
- by Chon, Seung-Hyun Mar 28, 2025 06:38am
- Lotte Biologics has been making smooth progress, building a new plant since its launch. Three years after its launch, it has received a total of KRW 800 billion from its parent company and is speeding up the construction of its Songdo plant. The US plant, which was acquired 3 years ago, also generated more than KRW 200 billion in sales every yea
- Company
- Shaperon discusses licensing out Nugel technology to Europe
- by Lee, Seok-Jun Mar 28, 2025 06:38am
- On the 27th, Shaperon announced that it has recently entered into discussions with global pharmaceutical companies about licensing out its next-generation atopic dermatitis treatment, NuGel, at Bio Europe Spring 2025, which was held in Europe. The company emphasized that it is accelerating the process of securing the company’s fiscal sou
- Company
- LigaChem Biosciences invests ₩36.6B in its UK partner
- by Cha, Jihyun Mar 27, 2025 05:54am
- LigaChem Biosciences announced on the 21st that it will invest USD 25 million (about KRW 36.6 billion) in its partner, UK-based Iksuda Therapeutics, to participate in management. The first USD 15 million was invested in the fourth quarter of last year. The additional USD 10 million will be invested in the middle of this year. After the in
- Company
- ADC mkt leader Daiichi-Sankyo's R&D drive
- by Whang, byung-woo Mar 27, 2025 05:54am
- Daiichi-Sankyo, a company leading the antibody-drug conjugate (ADC) market, is expanding its R&D capacity through the 'Expand & Extend'-based strategy. Daiichi-Sankyo plans to focus on expanding and strengthening access through the DXd-ADC platform, which is a basis for the company's chief pipeline. Daiichi-Sankyo's chief ADC drug is En
- Company
- Alopecia areata drug Litfulo may be prescribed hospitals
- by Eo, Yun-Ho Mar 27, 2025 05:54am
- The new drug for alopecia areata, Litfulo, has landed in general hospitals in Korea. According to industry sources, Pfizer Korea's new Janus kinase (JAK) inhibitor Litfulo (ritlecitinib) has passed the drug committees (DCs) of medical institutions such as Severance Hospital, Jeonbuk National University Hospital, and Chungnam National Univ
- Company
- Ja Q Bo ₩9B, K-CAB ₩8.2B, Fexuclue ₩4.7B
- by Chon, Seung-Hyun Mar 27, 2025 05:54am
- Homegrown P-CAB class new drugs for gastroesophageal reflux disease (GERD) have begun to generate export sales. Onconic Therapeutics’ Ja Q Bo generated significantly more overseas sales than domestic sales due to the effect of its licensing out deals. HK Inno.N's K-CAB and Daewoong Pharmaceutical's Fexuclue have begun to generate export sales i
- Company
- Abbott, the undisputed CGM leader seeks to expand mkt
- by Whang, byung-woo Mar 26, 2025 06:01am
- Abbott, a leading player in the continuous glucose monitoring (CGM) market, is seeking to expand its influence through collaboration with a medical data platform. The goal is to provide an improved blood glucose management solution that goes beyond simply collecting data and provides a comprehensive analysis of the patient's condition. On
- Company
- Cosentyx’s reimb for hidradenitis suppurativa unclear
- by Eo, Yun-Ho Mar 26, 2025 06:01am
- Discussions regarding the expansion of insurance reimbursement coverage for Cosentyx, a treatment option for hidradenitis suppurativa that emerged a decade after Humira, remain stalled. Novartis Korea applied then voluntarily withdrew the application for its interleukin (IL)-17A inhibitor Cosentyx (secukinumab) to extend its reimbursement
- Company
- Leclaza-Rybrevant combo rises as first-line treatment option
- by Moon, sung-ho Mar 26, 2025 06:01am
- The Leclaza-Rybrevant combination therapy, which has emerged as a standard treatment for lung cancer, is expected to be used in earnest in the domestic clinical market. This is because the larger hospitals have launched patient programs for the combination, based on results showing that the combination thearpy’s progression-free survival (P
- Company
- Beijing Hanmi Pharm posts two-fold sales·three-fold profit
- by Kim, Jin-Gu Mar 26, 2025 06:00am
- Beijing Hanmi Pharmaceutical, a local subsidiary of Hanmi Pharm in China, posted sales that approximately doubled over the past four years. The net income for the year increased more than threefold. Despite staggering performance last year, the company anticipated to be a temporary one. According to the Financial Supervisory Service on March
